The Centers for Medicare and Medicaid Services is presenting its requirement that Medicare coverage for Alzheimer’s drugs will be conditioned on sponsors conducting registry-based studies as significantly less onerous than its earlier proposed randomized clinical trial requirement – and it is.
But that doesn’t mean the criteria CMS outlines for the registry studies will be easy to meet, former CMS chief...